Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?
After a few years of stagnation, this stock is soaring.
Overview
Moderna (NASDAQ: MRNA) has been one of the market's hottest stocks this year, surging more than 500% so far. The biotech stock has delivered these kinds of gains before, soaring more than 2,000% from the start of 2020 through early August of 2021, as its coronavirus vaccine delivered blockbuster revenue. Moderna was one of the stars of early pandemic days, bringing a vaccine to market in a matter of months -- a vaccine that would become one of the world's top-selling pharmaceutical products.
In the years to follow, though, Moderna's earnings picture and stock performance fell into the doldrums. Demand for the vaccine, its only product at the time, slid in later pandemic days, and Moderna found itself cutting costs to account for this shift. Meanwhile, the company gained other product approvals and advanced its pipeline, but investors didn't immediately jump on board. In fact, the stock slid in recent years.
Details
This year, however, investors have gotten excited about Moderna again, particularly in response to the progress of its personalized cancer vaccine candidate. That's supercharged Moderna's stock performance, and as a result, Moderna now trades 61% above Wall Street's average price target. Is it time to sell? Let's find out.
Source
Originally published at www.fool.com.